NEWS
IN THE NEWS
ICER raises cost-effective price for Pfizer’s ATTR drug in final analysis but still calls for hefty discount aliu Mon, 10/21/2024 – 15:00
https://www.fiercepharma.com/pharma/icer-raises-cost-effective-price-pfizers-attr-drug-final-analysis-still-calls-hefty-discount
Radiopharma CDMO Nucleus lays out plan to triple manufacturing capacity, add 100 jobs kdunleavy Mon, 10/21/2024 – 14:50
https://www.fiercepharma.com/manufacturing/radiopharma-cdmo-nucleus-lays-out-plan-boost-manufacturing-will-increase-access
Sanofi in ‘exclusive negotiations’ to sell 50% stake in €16B consumer health unit Opella esagonowsky Mon, 10/21/2024 – 11:35
https://www.fiercepharma.com/pharma/sanofi-exclusive-negotiations-sell-50-stake-eu16b-consumer-health-unit-opella
Novo plots US, EU approval filings after oral semaglutide shows cardio benefits in certain diabetes patients aliu Mon, 10/21/2024 – 09:44
https://www.fiercepharma.com/pharma/novo-nordisks-oral-semaglutide-reduces-heart-disease-risks-certain-diabetes-patients
Takeda details another round of layoffs in Massachusetts as restructuring drive rolls on fkansteiner Mon, 10/21/2024 – 10:27
https://www.fiercepharma.com/pharma/takeda-details-another-round-layoffs-ma-restructuring-drive-rolls
Activist investor Starboard sets its sights on J&J spinout Kenvue: WSJ zbecker Mon, 10/21/2024 – 10:39
https://www.fiercepharma.com/pharma/activist-investor-starboard-sets-its-sights-jj-spinout-kenvue-wsj